Ospedale S. Eugenio, ASL Roma 2
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases
The research program at Ospedale S. Eugenio focuses on hematologic malignancies and related blood disorders, aiming to test innovative therapies that improve survival and reduce disease burden. Current studies explore how targeted agents and immunotherapies can achieve deeper molecular remission in conditions such as acute lymphoblastic leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia.
- Targeted Bcl‑2 inhibition combined with monoclonal antibodies
- BTK inhibitor addition for resistant disease
- Tyrosine‑kinase inhibitor strategies in Ph+ leukemia
- MRD‑guided treatment adaptation
The site’s multidisciplinary team of five investigators collaborates closely with patients to assess treatment effectiveness and safety, fostering rapid translation of promising results into clinical practice.
Neoplasms
In the area of solid and blood‑cell cancers, Ospedale S. Eugenio conducts trials that evaluate novel drug combinations and transplantation approaches for diseases including acute myeloid leukemia, myelodysplastic syndromes, and myelofibrosis. The primary goal is to determine whether these new regimens can extend overall survival and achieve durable remission, especially in high‑risk patient groups.
- Molecularly targeted agents for NPM1‑mutated AML
- Hypomethylating therapies combined with stem cell transplantation
- Novel monoclonal antibodies to reduce residual disease
- Agents addressing anemia and thrombocytopenia in MDS
By integrating cutting‑edge science with patient‑centered care, the research unit seeks to bring forward safer and more effective options for individuals facing aggressive neoplastic conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 43 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 43 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ospedale S. Eugenio, ASL Roma 2
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Open-Label Study of Imetelstat Versus Best Available Therapy in Intermediate-2 or High-Risk Myelofibrosis Refractory to JAK-Inhibitors | Geron Corp. | Phase III | Not Recruiting | Apr 2021 | — |
IMP list
lock Showing 1 of 43 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 4 | Unknown | 2020-09-24 | 2021-09-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.